Abstract. Introduction. The rapid development of new radiotherapy technologies, such as intensity modulated radiotherapy (IMRT) or tomotherapy, has resulted in the capacity to deliver a more homogenous dose in the target. However, the higher doses associated with these techniques are a reason for concern because they may increase the dose outside the target. In the present study, we compared 3DCRT, IMRT and tomotherapy to assess the doses to organs at risk (OARs) resulting from photon beam irradiation and scattered neutrons. Material and methods. The doses to OARs outside the target were measured in an anthropomorphic Alderson phantom using thermoluminescence detectors (TLD 100) 6 Li (7.5%) and
Introduction
Many modern radiotherapy techniques have been developed in recent decades in response to the need to increase the radiation dose to the tumour, while delivering the radiation therapy as accurately as possible. Such advanced techniques include intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiation therapy (SBRT), and tomotherapy (TT), among others.
While it is accepted that these treatments deliver more accurate radiation, there are concerns regarding the doses delivered to the nearby organs at risk (OARs). Moreover, the high energy levels used in these treatments may result in signifi cant scatter irradiation. For this reason, it is essential to measure and calculate these low doses; however, doing so presents many challenges [1] [2] [3] [4] , primarily because the treatment planning systems (TPS) do not calculate doses outside the planning target volume (PTV) more than a few centimetres from the edge of the radiation fi eld. According to the International Commission on Radiological Protection (ICRP), it is necessary to estimate doses outside the PTV from The neutron dose from 20 MV X-ray beam accounted for 0.5% of the therapeutic dose prescribed in the PTV. The further from the fi eld edge the higher the contribution of this secondary radiation dose (from 8% to ~45%). Conclusion. For tomotherapy, all OARs outside the therapeutic fi eld are well-spared. In contrast, IMRT achieved better sparing than 3DCRT only in the bladder. The photoneutron dose from the use of high-energy X-ray beam constituted a notable portion (0.5%) of the therapeutic dose prescribed to the PTV.
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all sources in order to assess total stochastic risks, and thus adequately justify radiation exposure in patients treated with radiotherapy (RT) [5] .
Numerous studies have evaluated the radiation doses in a body during IMRT and the conventional three-dimensional conformal radiotherapy (3DCRT) [6] [7] [8] [9] [10] , although fewer have done so for tomotherapy. We carried out the present study in which we compared 3DCRT, IMRT and tomotherapy to assess the doses received by the organs at risk (OARs) resulting from photon beam irradiation and scattered neutrons. The study was performed in an anthropomorphic phantom in a prostate cancer model, with dose measured with lithium fl uoride chips (TLD 100).
Material and methods

Treatment plan preparation
For measurements of low doses in the body, an anthropomorphic phantom with special thermoluminescent dosimeter (TLD) inserts were prepared. The thickness of each layer in the Alderson phantom is 2.5 cm and the distance between the dosimetric points is 3 cm, thus allowing for an accurate determination of doses in the selected organs. The doses in OARs located outside the target were measured in the anthropomorphic Alderson phantom using thermoluminescence detectors (TLD) 100 ( 6 Li (7.5%) and 7 Li (92.5%)); (Harshaw Chemical Company). In the fi rst phase, the computed tomography (CT) scans were acquired. Subsequently, the clinical target volumes (CTV) were contoured for the prostate (CTV1), lymph nodes (CTV2) and OARs (bladder, rectum, lung, thyroid and testes). The target consisted of the whole pelvic lymph nodes and the prostate gland with seminal vesicles.
In the next stage, three treatment plans were calculated for each of the techniques: 3DCRT (20 MV), IMRT (20 MV) and tomotherapy (6 MV). The dose prescription for each technique was 2 Gy per fraction up to the total dose of 76 Gy. These energies were used according to the standard protocol for patients with prostate cancer at our institution. For organs inside or close to the treatment fi elds (rectum, bladder, testes), the doses were read from the TPS. However, the readout of doses for thyroid and lung from the TPS was not possible because commercial systems do not calculate doses at such long distances outside of the target volume.
The aim of each treatment plan was to provide therapeutic dose of 2 Gy using three different techniques, with maximum protection of organs at risk. All parameters of the treatment plans were applied according to the protocol used in our institute for patients with prostate cancer. The treatment plans for 3DCRT technique consisted of four beams -box technique (0, 90, 180 and 270). The total number of Monitor Units (MU) was 163 per fraction. For IMRT, the dose distribution was prepared using seven coplanar beams with the fi eld geometry of 0°, 50°, 105°, 145°, 215°, 255° and 300°. The total number of MUs was 779 per fraction. The tomotherapy plan was generated with the Hi-Art Treatment Planning System (version 4.0.4.17). Based on results from the Skórska et al. [11] study, we used the treatment planning parameters presented in Table 1 . The actual modulation factor was 1.95. The dose was calculated using a superposition/convolution algorithm with a fi ne dose calculation grid (0.254 cm × 0.254 mm × 0.3 cm). The plan was optimized to reduce the dose to the OARs to a minimum, while the dose to the PTV was maintained in accordance with the ICRU 83 Report [12] . The irradiation time was 407.5 s and the expected number of MUs was 5863 [13] . Figures 1 and 2 show the dose distribution in the phantom for plans 3DCRT, IMRT and tomotherapy.
Dose measurements
A total of 100 TLDs per treatment modality were calibrated at 1 Gy. Of these, 73 were chosen for measurements, with a calibration factor below 3%. This means that the difference between different calibration measurements was not more than 3% [14] . 
Neutron measurements
Neutron fl uence rate [cm -2 ·s -1 ] at chosen points inside the Rando ® phantom was measured in terms of neutron activation analysis (NAA) with the use of gold foils in the shape of discs that were 0.5 cm in diameter and having a mean surface density of 0.108 g/cm 3 . The induced activity of 198 Au, measured with the semiconductor gamma spectrometer in terms of net area under the peak 411 keV, was directly used to obtain the slow neutron fl uence rate values. On the basis of an additional (without an anthropomorphic phantom) measurement of thermal neutron fl uence rate  th in the linac isocenter, the quantity of neutron source strength Q [s -1 ] was estimated using relation (1) . Subsequently, the fast component, which contains direct and scattered fractions of neutron flux, was calculated using Eq. (2) at a distance of r [cm] from the beam axis, where OARs were located with respect to the therapeutic plan isocenter and for the surface S [cm 2 ] of the room walls of the linac bunker.
(1) (2) Neutron dose equivalent at each measuring point (the same as for photon dose measurements) was determined using fl uence-to-dose conversion coeffi cients (C F-D ). These were calculated from Eq. (3) involving the average neutron energy (E avg ), adopted from AAPM Report 19 [15] , separately for slow and fast components of neutron fl ux. Based on the analysis of neutron spectra given in the literature, [16] [17] [18] the average neutron energy were taken as 0.2 eV and 0.5 MeV for slow and fast components, respectively. All quantities connected with neutron radiation were referred to the therapeutic dose of 1 Gy deposited in the target volume [19] [20] [21] [22] [23] .
(3)
Results
Mean dose to the bladder using TPS
The bladder is the organ located closest to the PTV, and therefore, it is possible to measure the dose using the TPS. Notable differences among the three RT techniques were observed for the bladder volume included in the therapeutic fi eld. Use of the 3DCRT technique resulted in larger doses to the bladder vs. IMRT, as shown in Table 2 , which shows the mean dose to the various bladder regions for 3DCRT, IMRT and tomotherapy (TT). Table 3 shows the comparison of out-of-fi eld doses between 3DCRT, IMRT and tomotherapy. As shown in Table 3 , the scattered radiation from the patient predominates in the region near the therapeutic fi eld. However, as the distance from the fi eld edge increases, the radiation scattered by the collimator, the transmission through the collimator and machine leakage becomes more predominant [24] . A higher beam energy leads to an increase in the out-of-fi eld dose. The effect is enhanced in the proximity of the 
Dose measurements
3DCRT
For 3DCRT, the bladder was located within the radiation fi eld, and therefore, received a dose that was nearly equal to the dose to the prostate. The dose in the thyroid, located approximately 60 cm from the central beam axis (CAX), was 0.621 Gy, which is about 1% of the CAX. The dose in the lung equalled 1.3% of the total dose. In the phantom, the TLDs were located on the surface of lungs, both at peripheral and central parts. The detectors located near the pelvis yielded higher dose measurements than TLDs located in other areas. The mean dose to the bladder with 3DCRT was 80.6 Gy. The testes were located close to the radiation fi eld and received 4.4% of the total dose.
IMRT
For IMRT, the bladder was located partially in the fi eld, and received a dose similar to that received by the prostate. The radiation fi eld was larger than in 3DCRT, and consequently the dose to some OARs was higher; however, the dose to the bladder was lower than with 3DCRT (53.7 Gy vs. 80.6 Gy) because it was outside the fi eld of radiation. The total IMRT dose to the thyroid gland was approximately 5 times higher than with 3DCRT (2.88 Gy vs. 0.62 Gy), representing about 4% of the dose in the PTV. In the lungs, the measured dose was 4.8 Gy.
The dose in the testes was 2 Gy larger than that achieved with 3DCRT.
Tomotherapy
For tomotherapy, the total doses (for complete treatment process to 76 Gy) to the thyroid gland, lungs, bladder, and testes were, respectively, 0.6, 0.7, 34.7 and 4.4 Gy.
Neutron dose results
The neutron effective dose (Table 4) did not vary signifi cantly across the whole body of the phantom for IMRT technique 1 : the arithmetic mean over the complete results of photoneutron dose estimation is 5.777 mSv/Gy and the standard deviation of this mean value is 0.127. The dispersion of the results achieved at particular points across the phantom reaches only 19%. However, the dose tended to decrease as the distance from the central beam axis (CAX) increased, a phenomenon that is explained by the thermalization of neutrons and subsequent capture. The symmetrical (with respect to the long axis of the phantom/therapeutic couch) distribution of neutron fl uence can be observed in Fig. 3 . This distribution is connected with the specifi c treatment plan for IMRT technique implemented in the present research. The uncertainty of these values (given in Table 4 ) are high because they are affected by several factors, the most important of which is related to the net peak area dependent on the spectrometer counting statistics (when the activity of detection foil is assigned), and the fl uence-to-dose conversion coeffi cients used (10%).
Discussion
Modern radiotherapy systems deliver highly targeted doses. However, because TPS do not calculate doses more than few centimetres outside the PTV, organs outside the fi eld may receive high doses, leading to a multitude of adverse effects. In the present study, we evaluated three common RT modalities -IMRT, SBRT and tomotherapy -in a phantom model to determine the doses from both scattered and direct radiation delivered to the surrounding OARs. The main finding was that tomotherapy provided the best overall sparing of organs located outside the therapeutic fi eld. Surprisingly, 3DCRT achieved better sparing than IMRT for all organs except for bladder. In addition, the photoneutron dose (re- sulting from the use of high-energy X-ray beam) constituted approximately 0.5% of the therapeutic dose prescribed in the PTV. As expected, doses to the remaining points were higher for IMRT, but the magnitude of doses at the more distant points became quite small. The differences can be explained by considering the different components of the peripheral dose: (1) the linear accelerator head leakage, which affects the entire body equally and is directly proportional to monitor units, (2) the internal scatter, which primarily affects tissues several centimetres from the beam edge and is directly proportional to fi eld size, and (3) the entrance and exit extra-target doses in the plane of beams will expose more tissues to lower doses in the plane of the beams.
Measuring low doses presents many challenges because the spectrum of the scatter radiation is unknown, and detectors must therefore be independent of the energy spectrum. Moreover, it is not possible to verify doses in OARs located outside the therapeutic fi eld in vivo. For this reason, anthropomorphic phantoms such as the Alderson phantom with special TLD inserts are needed. This phantom provides the ideal conditions for dose verifi cation outside the target, and the TLDs are both precise and independent of the energy spectrum.
As discussed previously, the lack of information from TPS regarding doses outside the beam path is problematic. Similarly, the fact that the TPS does not account for neutron radiation, which in modern RT techniques can constitute a signifi cant part of the dose to organs outside the target, presents an additional problem. It is clear that when high-energy X-ray beams are used in radiotherapy treatment, the presence of secondary neutron radiation should also be taken into account. Computer simulations of the spectra of therapeutic photon beams [25, 26] have shown that up to 30% of photons could have energy above the threshold of nuclear reactions (, n) for heavy elements constituting the accelerator head. These photonuclear interactions are the main source of fast neutrons, produced mostly via giant dipole resonance (GDR) [27] . As the photoneutrons leave the linear accelerator (linac), their energy spectrum becomes moderated. Therefore, in the isocenter, two main components are distinguished: the fast one with an average energy of about 0.5 MeV, and the slow one with the distribution peaked at thermal energy (E Av = 0.025 eV) and a tail on the high-energy site (E Av = 0.05 MeV), as several studies have shown [28, 29] . Since the linear energy transfer (LET) and the relative biological effectiveness (RBE) of neutrons depend strongly on their energy, these two main components should be taken into account when evaluating the additional dose from secondary radiation during radiotherapy.
A somewhat surprising fi nding of this study was that IMRT resulted in worse OAR sparing than 3DCRT. The reasons for this difference may be explained by the longer beam-on time required with IMRT, and the consequent increased exposure to leakage radiation. Moreover, the use of more than four fi elds resulted in a larger volume of tissue exposed to relatively low doses [30, 31] . As compared to the conventional 3DCRT, IMRT requires the emission of more MUs to deliver the same dose to PTV. Also, the fi eld size does not remain constant during the whole procedure. These two factors greatly infl uence the production of photoneutrons, as well as the contribution of fast neutrons (of higher RBE), which is connected with the fi eld size. The effective neutron dose relates also to the depth inside the body (phantom). Multi-directional dose delivery in the IMRT technique causes the geometry of neutron irradiation to be more isotropic. To avoid neutron irradiation of asymmetrical OARs, changes in the treatment plan, such as the use of a different distribution of beam directions (i.e., not symmetrical), could be considered.
The bladder and testes, as accepted, received the highest dose because the OAR in 3DCRT was within the fi eld of radiation and very near the fi eld of radiation for IMRT and tomotherapy. In addition, neutron contamination from high-energy therapeutic beams (such as, the 20 MV IMRT beam) undoubtedly contributed to these doses. In other regions (pelvis, chest and eyes), the effective doses due to photoneutrons were estimated with the NAA method.
Limitations
The doses in OARs were measured under ideal conditions: there was no movement of the phantom during the treatment. In case of a real patient, these doses would be more variable depending on the organ motion or bladder and rectal fi lling. In the phantom, the dose measurements were clustered around the same range of values due to the stable nature of phantom geometry; in a live patient, this would not be the case, but for the organs placed at a distance of 50-60 cm from the isocenter, the movements can be insignifi cant.
Conclusion
Among the three treatment modalities evaluated in the present study, we found that tomotherapy provides the best OAR sparing. Surprisingly, 3DCRT provided better sparing than IMRT for all OARs except the bladder. The further from the fi eld edge the higher the contribution of this secondary radiation dose. The use of lower energies, when feasible, allows avoiding undesirable scatter radiation and its negative effects. The low doses and secondary radiation can have an impact on the normal tissues and OARs, therefore, more research in this area is needed. Research also requires relation doses in organ at risk to stochastic effects, which are the subject of another work of the authors.
